Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/2C-X/Neuroimaging & Brain Measures

2C-X for Neuroimaging & Brain Measures

2 papers and 1 clinical trial exploring 2c-x as a treatment for neuroimaging & brain measures.

CompoundPhenethylamine

2C-X

2C-X denotes a family of synthetic phenethylamine psychedelics defined by a 2,5-dimethoxyphenethylamine scaffold. 2C-B is the best-studied member, with emerging controlled human data benchmarking it against psilocybin and MDMA.

Full 2C-X profile
IndicationApproximately 264 million people globally suffer from depression, with PTSD affecting around 8 million adults in the United States each year.

Neuroimaging & Brain Measures

Recent advances in neuroimaging have shed light on the neurobiological mechanisms underlying the effects of psychedelics, particularly in the treatment of mental health disorders such as depression and PTSD. Studies involving compounds like psilocybin and MDMA have demonstrated significant changes in brain activity associated with therapeutic outcomes.

Full Neuroimaging & Brain Measures profile

Academic Research

2 papers
Open Accessindividual

The forgotten psychedelic: Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin

Using 7T resting-state fMRI in a double-blind, placebo-controlled crossover study, the authors show that acute 2C-B and psilocybin both reduce intra-network static connectivity while increasing between-network and subcortical–cortical coupling and brain complexity, but 2C-B causes less between-network desynchronisation and relative elevations in transmodal connectivity compared with psilocybin. These spatially divergent effects align with monoaminergic transporter and serotonergic receptor distributions and link transmodal-axis desynchronisation to behavioural measures, highlighting 2C-B as a distinct tool for psychedelic neuroscience and potential pharmacotherapies.

Published
February 3, 2026
Journal
Molecular Psychiatry
Authors
Mallaroni, P., Singleton, P., Mason, N. L., Satterthwaite, T. D., Ramaekers, J. G.
Paywallindividual

Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2, 5-dimethoxyphenethylamine (2C-B) in rats

This rat study investigates the behavioral, neurochemical, and EEG profiles 2C-B. 2C-B demonstrates biphasic effects on locomotion, initially inhibitory and then excitatory, contrasting with amphetamine which induces solely hyperlocomotion. Both compounds disrupt prepulse inhibition (PPI) of the startle reaction, albeit with different effects on acoustic startle response (ASR). In the nucleus accumbens (NAc), 2C-B increases dopamine levels but decreases 3,4-dihydroxyphenylacetic acid (DOPAC), suggesting potential psychotomimetic and addictive properties. EEG analyses reveal that low doses of 2C-B reduce power spectra and coherence, whereas high doses show biphasic effects on EEG power and coherence.

Published
July 29, 2012
Journal
Psychopharmacology
Authors
Páleníček, T., Fujáková, M., Brunovský, M., Horáček, J., Gorman, I., Balíková, M., Lukáš, R., Syslová, K., Kačer, P., Zach, P., Bubeníková-Valešová, V., Tylš, F., Kubešová, A., Puskarčíková, J., Höschl, C., Rambousek, L.

Clinical Trials

1 trial
CompletedPhase NA

Sub(acute) Profiling of 2C-B Versus Psilocybin

This interventional study (n=18), named PREDICT and conducted by Maastricht University, aims to comprehensively evaluate the acute and subacute effects of 2C-B compared to psilocybin and a placebo.

Started
August 4, 2021
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
NL8813

Explore further

Search all 2C-X papers Search all Neuroimaging & Brain Measures trials Full 2C-X profile Full Neuroimaging & Brain Measures profile